Tobira Therapeutics, Inc. (TBRA) [Rocket]

Overview

Tobira Therapeutics, Inc. (TBRA)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
02/14/2017	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/18/2017	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend]
11/14/2016	15-12B	Form 15-12B - Securities registration termination [Section 12(b)]
11/04/2016	SC 13D/A	Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend]
11/04/2016	4	Form 4 - Statement of changes in beneficial ownership of securities
11/03/2016	4	DP VI Associates, L.P. (10% Owner) has filed a Form 4 on Tobira Therapeutics, Inc.
11/03/2016	4	Form 4 - Statement of changes in beneficial ownership of securities

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
Revenues	0.0	0.0	0.0	0.0	-11.9
Revenue growth				-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	25.9
Gross profit	0.0	0.0	0.0	0.0	-37.8
Gross margin					318.7%
Selling, general and administrative				12.2
Research and development	24.7	12.2	12.4
General and administrative	10.9	7.8	2.8		7.0
EBITA	-35.5	-20.0	-15.2	0.4	-18.9
EBITA margin					159.4%
Amortization of intangibles				0.4
EBIT	-35.5	-20.0	-15.2	0.0	-18.9
EBIT margin					159.4%
Pre-tax income	-54.0	-23.8	-18.6	0.0	-19.2
Income taxes	-4.4	0.3	0.0	0.0	0.0
Tax rate	8.1%		0.0%		0.0%
Net income	-49.6	-24.1	-18.6	0.0	-19.2
Net margin					161.8%

Diluted EPS	($4.08)	($59.72)	($47.31)	$0.00	($86.86)
Shares outstanding (diluted)	12.2	0.4	0.4	0.2	0.2

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.